Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $33.00 price objective on the biotechnology company’s stock. Several other analysts have also weighed in on the company. TD Cowen started coverage […]
Vanguard Capital Wealth Advisors bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the second quarter, Holdings Channel reports. The institutional investor bought 6,135 shares of the biotechnology company’s stock, valued at approximately $219,000. A number of other large investors have also recently bought and sold shares of the business. Captrust […]
Commodore Capital LP lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 24.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,000 shares of the biotechnology company’s stock after purchasing an additional 112,889 shares during the quarter. […]
Platinum Investment Management Ltd. purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 76,208 shares of the biotechnology company’s stock, valued at approximately $1,936,000. Platinum Investment Management Ltd. owned approximately […]
Russell Investments Group Ltd. cut its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 8.3% in the first quarter, Holdings Channel.com reports. The firm owned 227,898 shares of the biotechnology company’s stock after selling 20,711 shares during the quarter. Russell Investments Group Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $5,789,000 as of its […]